XML 13 R20.htm IDEA: XBRL DOCUMENT
v3.20.1

13. Restructuring Costs (Notes) | 3 Months Ended
--- | ---
Mar. 31, 2020
Restructuring Costs [Abstract] |
Restructuring and Related Activities Disclosure [Text Block] | RESTRUCTURING COSTS Restructuring Costs for a Facility Closure In December 2018, we announced the closure of a small manufacturing facility outside Paris, France. From December 2018 to March 31, 2020, total expenses were $4.0 million. Restructuring charges for the facility closure are included in our Clinical Diagnostics segment's results of operations. The liability of $2.9 million as of March 31, 2020 consisted of $2.7 million recorded in Accrued payroll and employee benefits and $0.2 million recorded in Other current liabilities in the Condensed Consolidated Balance Sheets. The following table summarizes the activity for the facility closure restructuring reserves for severance and exit costs (in millions):
Balances as of December 31, 2019: |  | $ | 3.2 |
Cash payments |  | (0.3 | )
Balances as of March 31, 2020: |  | $ | 2.9 |
Restructuring Costs for European and North American Reorganization In November 2019, we announced our strategy-driven restructuring plan. We expect that a significant portion of the net savings resulting from this restructuring plan will be repurposed in alignment with our portfolio strategy. The restructuring plan includes a workforce reduction in Europe, the United States and Canada, and is expected to be incurred through 2020. The liability of $14.0 million as of March 31, 2020 was recorded in Accrued payroll and employee benefits in the Condensed Consolidated Balance Sheets. The amounts recorded were reflected in Cost of goods sold of $(1.5) million, in Selling, general and administrative expense of $(0.5) million and in Research and development expense of $(0.4) million in the Condensed Consolidated Statements of Income for the three months ended March 31, 2020. From November 2019 to March 31, 2020, total expenses were $22.9 million. The following table summarizes the activity of our European and North American reorganization restructuring reserves for severance (in millions):
|  | Life Science |  | Clinical Diagnostics |  | Total
Balances as of December 31, 2019: |  | $ | 6.2 |  |  | $ | 19.1 |  |  | $ | 25.3 |
Adjustment to expense |  | (0.3 | ) |  | (2.1 | ) |  | (2.4 | )
Cash payments |  | (2.9 | ) |  | (5.7 | ) |  | (8.6 | )
Foreign currency translation gains |  | (0.1 | ) |  | (0.2 | ) |  | (0.3 | )
Balances as of March 31, 2020: |  | $ | 2.9 |  |  | $ | 11.1 |  |  | $ | 14.0 |

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -URI http://asc.fasb.org/topic&trid=2175745 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RestructuringCostsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration